Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ.

N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.

PMID:
31971679
2.

A Case of Unilateral Dermopathy Possibly Related to Graves' Disease.

Rodia C, Menconi F, Mazoni L, Torregrossa L, Basolo F, Vitti P, Marcocci C, Marinò M.

Eur Thyroid J. 2019 Oct;8(5):278-282. doi: 10.1159/000500297. Epub 2019 Jun 11.

3.

Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

Marinò M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R, Marcocci C.

J Endocrinol Invest. 2019 Nov 5. doi: 10.1007/s40618-019-01141-3. [Epub ahead of print] Review.

PMID:
31691261
4.

A Case of Oculocutaneous Albinism in a Patient with Hashimoto's Thyroiditis.

de Gennaro G, Vitti P, Marinò M.

Eur Thyroid J. 2019 Jan;8(1):56-58. doi: 10.1159/000493730. Epub 2018 Oct 16.

5.

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.

Marinò M, Rotondo Dottore G, Ionni I, Lanzolla G, Sabini E, Ricci D, Sframeli A, Mazzi B, Menconi F, Latrofa F, Vitti P, Marcocci C, Chiovato L.

J Endocrinol Invest. 2019 Apr;42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub 2018 Aug 21.

PMID:
30132285
6.

Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.

Marinò M, Dottore GR, Leo M, Marcocci C.

Horm Metab Res. 2018 Dec;50(12):887-893. doi: 10.1055/a-0658-7889. Epub 2018 Aug 10. Review.

PMID:
30096720
7.

Selenium in Graves Hyperthyroidism and Orbitopathy.

Marinò M, Menconi F, Rotondo Dottore G, Leo M, Marcocci C.

Ophthalmic Plast Reconstr Surg. 2018 Jul/Aug;34(4S Suppl 1):S105-S110. doi: 10.1097/IOP.0000000000001136. Review.

PMID:
29933354
8.

Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Lanzolla G, Sabini E, Profilo MA, Mazzi B, Sframeli A, Rocchi R, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M.

J Endocrinol Invest. 2018 Dec;41(12):1417-1423. doi: 10.1007/s40618-018-0915-z. Epub 2018 Jun 19.

PMID:
29923059
9.

Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.

Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, Menconi F, Piaggi P, Sellari-Franceschini S, Nardi M, Latrofa F, Vitti P, Marcocci C, Basolo F, Marinò M.

JAMA Ophthalmol. 2018 Jun 1;136(6):613-619. doi: 10.1001/jamaophthalmol.2018.0806.

10.

Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.

Sabini E, Ionni I, Rocchi R, Vitti P, Marcocci C, Marinò M.

Eur Thyroid J. 2018 Jan;7(1):51-54. doi: 10.1159/000479629. Epub 2017 Aug 22.

11.

Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized clinical trial.

Sellari-Franceschini S, Rocchi R, Marinò M, Bajraktari A, Mazzi B, Fiacchini G, Lepri P, Dallan I, Vitti P, Marcocci C.

J Endocrinol Invest. 2018 Sep;41(9):1037-1042. doi: 10.1007/s40618-018-0847-7. Epub 2018 Feb 15.

PMID:
29450866
12.

Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin.

Latrofa F, Ricci D, Bottai S, Brozzi F, Chiovato L, Piaggi P, Marinò M, Vitti P.

Thyroid. 2018 Mar;28(3):288-294. doi: 10.1089/thy.2017.0052.

PMID:
29439614
13.

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO).

Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31.

PMID:
29396246
14.

High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.

Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M.

Thyroid. 2018 Mar;28(3):386-394. doi: 10.1089/thy.2017.0430. Epub 2018 Feb 9.

PMID:
29336220
15.

Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).

Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M.

J Endocrinol Invest. 2018 Jul;41(7):815-820. doi: 10.1007/s40618-017-0809-5. Epub 2017 Dec 18.

PMID:
29256181
16.

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Sabini E, Leo M, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M.

Eur Thyroid J. 2017 Sep;6(5):263-270. doi: 10.1159/000477803. Epub 2017 Jun 26.

17.

Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Leo M, Sabini E, Ionni I, Sframeli A, Mazzi B, Menconi F, Molinaro E, Bianchi F, Brozzi F, Santini P, Elisei R, Nardi M, Vitti P, Marcocci C, Marinò M.

J Endocrinol Invest. 2018 Mar;41(3):357-361. doi: 10.1007/s40618-017-0754-3. Epub 2017 Aug 30.

PMID:
28856610
18.

Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M.

J Endocrinol Invest. 2018 Feb;41(2):193-201. doi: 10.1007/s40618-017-0718-7. Epub 2017 Jun 27.

PMID:
28656526
19.

Selenium in the Treatment of Thyroid Diseases.

Marinò M, Marcocci C, Vitti P, Chiovato L, Bartalena L.

Eur Thyroid J. 2017 Apr;6(2):113-114. doi: 10.1159/000456660. Epub 2017 Mar 1. No abstract available.

20.

Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Currò N, Konuk O, Marinò M, Mitchell AL, Stankovic B, Törüner FB, von Arx G, Zarković M, Wiersinga WM.

Orphanet J Rare Dis. 2017 Apr 20;12(1):72. doi: 10.1186/s13023-017-0625-1.

Supplemental Content

Loading ...
Support Center